Indicated for: breast cancer
Route of administration: oral
Substance: elacestrant (antineoplastic agent)
ATC: L02BA04 (Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-estrogens)
Elacestrant is a medication used in the treatment of certain types of breast cancer, especially in postmenopausal women with hormone receptor-positive tumors. This medicine works by blocking estrogen receptors, thereby reducing the stimulation of hormone-dependent cancer cells. Elacestrant may be recommended when other hormonal therapies are no longer effective.
Elacestrant is usually administered as tablets, according to the oncologist’s instructions. The dose and duration of treatment are determined individually, based on the patient’s general condition and response to therapy. It is important to take the medication regularly and not to stop treatment without medical advice.
Side effects may include nausea, fatigue, headaches, hot flashes, or digestive disturbances. In some cases, changes in blood test results or allergic reactions may occur. If unusual or severe symptoms appear, it is recommended to contact your doctor immediately.
Elacestrant provides an additional option for patients with advanced breast cancer, helping to slow disease progression. Careful monitoring and constant communication with the medical team are essential for the safety and effectiveness of the treatment.